A story on fusion proteins in the Aug. 21, 2000, issue of BioWorld Today incorrectly reported on a 48-week Phase study. It should have said Trimeris Inc.'s candidate T-20 was tested in combination with approved anti-retroviral drug, not with Progenics Pharmaceuticals Inc.'s PRO 542. T-20 and PRO 542 have shown in vitro synergy, however. Editor's Note: The correction will be made Tuesday in BioWorld Online.

No Comments